The present study concludes that miR-124-3 methylation is not only a potential diagnostic biomarker for early-stage OSCC but also acts as a tumor suppressor by directly targeting LRRC1, thereby inhibiting the proliferation and migration of OSCC cells. The gene discussed is LRRC1; the disease is neoplasm.